摘要
目的评价心脑血管疾病高危住院患者的血脂水平,及临床医师是否按照美国胆固醇教育计划成人高胆固醇血症检测评估和治疗专家委员会第三次报告(NCEP-ATPⅢ)中提出的标准给予他汀类或其他药物干预,为临床提供规范、合理用药的依据。方法采取回顾性研究方法,运用NCEP-ATPⅢ中的标准,评价在两个不同时期(2008年、2010年)患者在院期间降脂药物用药状况,并进行对比分析。结果 2010年心脑血管病高危组与非心脑血管病组住院患者的总胆固醇、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)比较,差异无统计学意义(P>0.05),2010年心脑血管高危病组与非心脑血管疾病组的干预情况差异有统计学意义(P<0.05)。2008、2010年的总体及各科用药情况有较大区别。结论 2010年的心脑血管高危病组患者用药比例明显高于2008年同组患者,临床医师对血脂异常干预意识有明显提高,但仍未完全按照NCEP-ATPⅢ标准给予患者规范、合理的干预,需进一步改善。
Objective To evaluate the blood lipid level of high risk hospital patients with angiocardiopathy and cerebrovascular diseases.Whether the clinician administrated this kind of patients statins or other drugs according to the standards in NCEP-ATP Ⅲ report so as to provide a normal and rational administration stand for clinic.Methods According to the standards in NCEP-ATP Ⅲ report,the condition of antihyperlipidemic agents use of high risk hospital patients with angiocardiopathy and cerebrovascular disease was evaluated through retrospective study.The data at different time(2008,2010)were compared.Results The value of cholesterol total,high density lipoprotein(HDL)value,the low density lipoprotein(LDL)value and cholesterol total/HDL of the high risk hospital patients with angiocardiopathy and cerebrovascular disease were not significantly different from the hospital patients with non-angiocardiopathy and cerebrovascular disease.There were differences in change of antihyperlipedemics between the 2 years.Conclusion The ratio of medication in the high risk hospital patients with angiocardiopathy and cerebrovascular disease in 2010 was higher than that in 2008.The clinicians′ cognition of using drugs for hospital patients with blood-fat abnormality was obviously improved but still not totally base on the standards in NCEP-ATP Ⅲ report to provide normal and rational administration for patients.
出处
《实用药物与临床》
CAS
2012年第10期657-659,共3页
Practical Pharmacy and Clinical Remedies
关键词
心脑血管病高危住院患者
血脂异常
降脂药物
对比调查
High risk hospital patients with angiocardiopathy and cerebrovascular disease
Blood lipid abnormality
Antihyperlipidemics
Comparative survey